```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[S. 5206 Introduced in Senate (IS)]

<DOC>

118th CONGRESS
  2d Session
                                S. 5206

    To require a report on foreign investment in the pharmaceutical 
                     industry of the United States.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                           September 25, 2024

 Ms. Warren (for herself and Mr. Rubio) introduced the following bill; 
which was read twice and referred to the Committee on Banking, Housing, 
                           and Urban Affairs

_______________________________________________________________________

                                 A BILL

 
    To require a report on foreign investment in the pharmaceutical 
                     industry of the United States.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``United States Pharmaceutical Supply 
Chain Review Act''.

SEC. 2. REPORT ON FOREIGN INVESTMENT IN PHARMACEUTICAL INDUSTRY.

    (a) In General.--Not later than 1 year after the date of the 
enactment of this Act, and annually thereafter, the Federal Trade 
Commission (in this section referred to as the ``Commission''), in 
consultation with the Secretary of Commerce, shall submit to the 
appropriate congressional committees, the Secretary of Health and Human 
Services, the Committee on Foreign Investment in the United States, and 
the Commissioner of Food and Drugs, a report on foreign investment in 
the pharmaceutical industry of the United States.
    (b) Elements.--The report required by subsection (a) shall include 
an assessment of--
            (1) the supply chain of the pharmaceutical industry of the 
        United States and the effect of concentration and reliance on 
        foreign manufacturing within that industry;
            (2) the effect of foreign investment in the pharmaceutical 
        industry of the United States on domestic capacity to produce 
        drugs and active and inactive ingredients of drugs;
            (3) the effect of foreign investment in technologies or 
        other products for sequencing or storage of DNA, including 
        genome and exome analysis, in the United States, including the 
        effect of such investment on the capacity to sequence or store 
        DNA in the United States; and
            (4) the effect of pharmaceutical manufacturers in the 
        United States relocating manufacturing facilities to other 
        countries on domestic capacity to produce drugs and active and 
        inactive ingredients of drugs.
    (c) Authority.--The Commission shall have authority under section 6 
of the Federal Trade Commission Act (15 U.S.C. 46) to conduct the 
studies required to prepare the report required by subsection (a).
    (d) Publication.--The Commission shall publish an unclassified 
summary of the report required by subsection (a) on a publicly 
available internet website of the Commission.
    (e) Appropriate Congressional Committees Defined.--In this section, 
the term ``appropriate congressional committees'' means--
            (1) the Committee on Banking, Housing, and Urban Affairs, 
        the Committee on Health, Education, Labor, and Pensions, the 
        Committee on Armed Services, the Committee on Foreign 
        Relations, the Committee on Commerce, Science, and 
        Transportation, and the Committee on Appropriations of the 
        Senate; and
            (2) the Committee on Financial Services, the Committee on 
        Energy and Commerce, the Committee on Armed Services, the 
        Committee on Foreign Affairs, and the Committee on 
        Appropriations of the House of Representatives.
                                 <all>
```